semaj83/ctmatch_classification huggingface dataset:
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.5-1.0,  Haemophilus Influenzae Type b (Hib) Infection Infants 6-12 months of age  Prior Hib vaccine administration History of serious reaction(s) following vaccination Any vaccination within 14 days of study vaccination Known or suspected immune impairment For additional entry please refer to the protocol
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Thyroidectomy Distress Surgery (a) a minimally invasive follicular thyroid carcinoma ≤4 cm in diameter, or (b) a papillary thyroid carcinoma ≤2 cm in diameter  (a) previous neck operations (b) age <21 or >65 years (c) prior vocal fold paralysis or a history of voice or laryngeal disease requiring therapy (d) a malignancy with definite extrathyroid invasion, multiple lateral neck node metastasis, perinodal infiltration at a metastatic lymph node, or distant metastasis; and/or (e) a lesion located in the thyroid dorsal area (especially adjacent to the tracheoesophageal groove) caused by possible injury to the trachea, esophagus, or recurrent laryngeal nerve (RLN)
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 1.083-4.917,  Haemophilus Influenzae Type b (Hib) Infection Infants 13-59 months of age  Prior Hib vaccine administration History of serious reaction(s) following vaccination Any vaccination within 7 days of study vaccination Known or suspected immune impairment Premature (before 37th week of gestation) or birth weight less than 2500g For additional entry please refer to the protocol
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Abscess Patients presenting to the Civic Campus emergency department of The Ottawa Hospital with an abscess less than 5 cm diameter, as judged by the attending emergency physician (measurement with tape measure for diameter) between the hours of 7 am and 10 pm will be approached for possible enrollment. Ultrasound will be used to assess the appropriate  Patients under the age of 18 years Patients with a Glasgow coma scale score of <15 (i.e. not completely alert and oriented) Patients suspected of having necrotising fascitis Patients with hemodynamic instability (defined as SBP <90, and/or HR >110) Patients admitted to hospital Patients who are neither French nor English speaking Patients who are not available for telephone follow-up (i.e. homeless) Ultrasound image demonstrates that the abscess is not compressible (generally indicates that the contents of the cyst includes solids, which would not be amenable to aspiration) Ultrasound demonstrates that there is no abscess to manage Patients with perianal abscesses who have either Crohn's disease or ulcerative colitis or known perirectal fistula
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 8.0-21.0,  Cystic Fibrosis With Mild to Moderate Lung Disease CMRI of Lung Perfusion Lung Perfusion Lung Vascularization Research subjects must meet the following Age 8 years to age 21 years Weight > 20kg Diagnosis of cystic fibrosis confirmed by a prior sweat chloride evaluation of > 60 mmol/liter or by two identified CFTR mutations on genetic analysis Able to perform acceptable and repeatable spirometry per American Thoracic Society/European Respiratory Society (ATS/ERS) joint consensus criteria Have valid spirometry data for at least 3 years Must have mild to moderate lung disease (Mild lung disease will be defined as an FEV1%p of 80-99% predicted. Moderate lung disease will be defined as an FEV1%p of 60-79% predicted.) If under the age of 18, the subject must assent to participation in the study, and the subject's parent or guardian must be able to give written informed consent and comply with the requirements of the study protocol If 18 years of age or older, the subject must be able to give written parental permission and comply with the requirements of the study protocol For female subjects: negative serum pregnancy test and must be willing to use contraception during study participation  Research subjects will be excluded from the study based on History of CF-related liver disease with portal hypertension Currently smoking cigarettes or other tobacco products Use of daytime oxygen supplementation Previous organ transplantation Unstable or uncontrolled hypertension Ongoing use of oral corticosteroids For female subjects: pregnancy or lactation and unwillingness to use contraception during study participation Any hemodynamically significant congenital or acquired cardiac disease or significant cardiomyopathy, hematologic disease (i.e. hemoglobinopathies), or pulmonary disease associated with an increased risk of pulmonary perfusion defects or pulmonary hypertension other than as an outcome of CF History of renal and/or hepatic insufficiency, defined as cystatin-C level that exceeds normal range and a previous diagnosis of liver cirrhosis
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 3.0-12.0,  Tonsillectomy children age 3-12 years ASAI,II  contraindication for usage of Ketamine, dexamethasone upper respiratory tract infection increase intracranial pressure( ICP) history of allergy ,seizure,psychiatric illness, , bleeding disorders chronic usage of analgesic ,antiemetic ,stroied drugs two weeks before surgery history of peritonsillar abscess, , tonsillitis within two weeks, -
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 1.0-1.559,  Haemophilus Influenzae Type b (Hib) Infection Infants 365-569 days of age  Subjects who already received a booster dose of Hib vaccine History of serious reaction(s) following vaccination Any vaccination within 7 days of study vaccination Known or suspected immune impairment
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Peritonsillar Abscess Criteria:patients with PTA in ages 18-65, who agreed to join the research -  cave to dypiron and/or tramadol, pregnant women, mental illness,soldiers
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Dysphagia The Stroke Center inpatients and outpatients with known or suspected dysphagia can be included for study as well as patients who are admitted specifically for this protocol. (Difficulty swallowing food or pills,changed swallowing ability,coughing or choking when eating, shortness of breath during swallowing, food backing up into the mouth or nasal passage, fever or voice changes after swallowing, pain when swallowing, unexplained loss of weight  Patients who are severely demented or severely compromised will be excluded if they do not have sufficient cognitive ability to follow directions. Non-ambulatory patients will be excluded if they cannot be braced or supported within the fluoroscopy unit. Highly agitated individuals will also be excluded if they are unable to remain confined in the equipment
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 2.0-5.0,  Crossbite Openbite Drooling healthy children aged 3-4 years that use a pacifier  children suffering from a chronic or developmental disease that can affect the orofacial region finger sucking children children suffering from low muscle tonus, abnormal drooling
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peritonsillar Abscess referring doctor suspects peritonsillar abscess patient is voluntary patient has daily access to his/her e-mail patient speaks and understands Finnish of Swedish female patients have adequate birth-control method patient has peritonsillar abscess  allergy to penicillin allergy to metronidazole use of metronidazole in preceding one month pregnancy breast-feeding renal insufficiency liver insufficiency alcoholism (drunk at least once a week) participant in another clinical trial at the moment treatment of peritonsillar abscess requires in-patient care
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.5-6.0,  Infections, Respiratory Tract Subjects who the investigator believes that parent(s)/ legally acceptable representative can and will comply with the requirements of the protocol A male or female child between, and including, six to 72 months of age at the time of enrolment Written informed consent obtained from the parent(s)/ legally acceptable representative of the subject No antibiotic therapy within four weeks prior to the visit No cystic fibrosis or known major immunodeficiency such as agammaglobulinaemia, T cell deficiency or Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome No documented evidence or suspicion of gastroesophageal reflux disease No evidence of an upper viral respiratory infection four weeks prior to the visit In addition, all subjects regarded as 'cases' must satisfy all the following at study entry Persistent cough greater than eight weeks No response to five-day prednisolone treatment  Concurrently participating in another study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product Use of any investigational or non-registered product within 30 days prior to study procedures, or planned use during the study period Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination Child in care
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.5-3.0,  Seasonal Influenza; Influenza; Influenza Due to Unspecified Influenza Virus Human Influenza Male and female previously unvaccinated healthy children aged 6 to <36 months  Any known or suspected impairment of the immune system, any serious disease Any subjects receiving licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study Individuals who have had influenza vaccine or documented suspected influenza disease prior to day 1
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.164-0.329,  Diphtheria Pertussis Tetanus Hepatitis B Haemophilus Influenzae Infections Infants are at age of DTP vaccination of the local EPI program (60-120 days old) and free from any obvious health problems Have a normal gestational age (≥ 37 weeks); birth weight > 2.5 kg There is no congenital disease detected through interview and clinical examination Already had or not yet received Hepatitis B vaccination at birth Do not have dermatological diseases such as eczema, allergies Parent or legal guardian voluntarily provides consent for their child for participation in the study by signing the informed consent and agrees to comply with all study procedures  Already vaccinated with DTP vaccine Have an acute infection at the time of study vaccination Contraindications to Quinvaxem Receiving treatment with systemic corticosteroids Currently participating in another clinical trial In receipt of a parenteral immunoglobulin preparation and/or blood/blood products since birth Parents intend to move to another location during the study (the next 12 months)
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.167-5.0,  Haemophilus Influenzae Type B Infection Male and female children 2 months to 5 years of age scheduled to receive vaccination  Contraindications to Vaxem™Hib Korean Prescribing information
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.5-5.0,  Healthy Healthy subjects aged from 6 months to 5years old of normal intelligence The subjects'guardians are able to understand and sign the informed consent Subjects established as healthy after medical history questioning,physical examination and clinical decision and in accordance with vaccination requirements of the experimental vaccine Subjects who can comply with the requirements of the clinical trial program according to the researcher's views Subjects who have never received group A, C polysaccharide meningococcal vaccine and type b haemophilus Influenzal vaccine Subjects with temperature ＜37°C on axillary setting  for the first dose Subject who has a medical history of Meningitis Subject that has a medical history of any of the following: allergies, seizures, epilepsy, encephalopathy history and so on Subject who is allergic with tetanus toxoid components Subject suffering from thrombocytopenia or other coagulation disorder may lead to contraindication to intramuscular injection Subject who has a history of allergic reactions Any known immunological dysfunction Had received gamma globulin or immune globulin, in the past two weeks Subject suffering from congenital malformations, dysgenopathy or serious chronic disease Any acute infections
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.5-5.0,  Group A, C Polysaccharide Meningitis Type b Haemophilus Influenza For the children (aged from 2 to 5 years old) Healthy subjects aged from 2 to 5 years old of normal intelligence The subjects' guardians are able to understand and sign the informed consent Subjects established as healthy after medical history questioning, physical examination and clinical decision and in accordance with vaccination requirements of the investigational vaccine Subjects who can comply with the requirements of the clinical trial program according to the researcher's views Subjects who have never received group A, C polysaccharide meningococcal vaccine and type b haemophilus Influenzal vaccine Subjects with temperature ＜37°C on axillary setting  Subject who has a medical history of Meningitis Subject that has a medical history of any of the following: allergies, seizures, epilepsy, encephalopathy history and so on Subject who is allergic with tetanus toxoid components Subject suffering from thrombocytopenia or other coagulation disorder may lead to contraindication to intramuscular injection Subject who has a history of allergic reactions Any known immunological dysfunction Had received gamma globulin or immune globulin, in the past two weeks Subject suffering from congenital malformations, dysgenopathy or serious chronic disease Any acute infections Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 50.0-55.0,  Herpes Esophagitis Vocal Fold Palsy Patient of Herpes esophagitis with vocal palsy presentation  Patient of Herpes esophagitis without vocal palsy presentation
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.25-0.417,  Meningitis Influenza Healthy subjects aged 3 to 5 months, normal intelligence The subjects' guardians are able to understand and sign the informed consent Healthy subjects confirmed by medical history questioning, physical examination and clinical decision and in accordance with vaccination requirements of the investigational vaccine Subjects who can comply with the requirements of the clinical trial program according to the researcher's views Subjects who have never received group A, C polysaccharide meningococcal vaccine and type b haemophilus Influenzal vaccine Subjects with temperature＜=37°C on axillary setting  for the first vaccination Subject who has a medical history of Meningitis Subject who has a medical history of any of the following: allergies, seizures, epilepsy, encephalopathy history and so on Subject who is allergic with tetanus toxoid components Subject suffering from thrombocytopenia or other coagulation disorder may lead to contraindication to intramuscular injection Subject who has a history of allergic reactions Any known immunological dysfunction Had received gamma globulin or immune globulin, in the past two weeks Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws Any acute infections in last 7 days